Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats

The aims of the present study were to investigate the effects of silymarin, an inhibitor of the P-glycoprotein efflux pump, on oral bioavailability of paclitaxel in rats, and to compare pharmacokinetic parameters of paclitaxel between a commercial formulation of paclitaxel (Taxol (R)) and a paclitaxel microemulsion. Oral bioavailability of paclitaxel in a Taxol (R) formulation was enhanced in the combination with silymarin (10 and 20 mg/kg). In particular, the mean maximum plasma concentration (C-max) and the mean area under the plasma concentration-time curve (AUC(0-t)) of paclitaxel in the Taxol (R) formulation were significantly increased 3-fold and 5-fold compared with control, respectively, following oral co-administration with 10 mg/kg of silymarin (p < 0.01). When the paclitaxel microemulsion was co-administered with silymarin (20 mg/kg) orally, it caused a maximum increase in the absolute bioavailability of paclitaxel (19%). In addition, the relative bioavailability of the paclitaxel microemulsion was 184% as compared to Taxol (R) after oral dosing, whereas the mean time required to reach C-max (T-max) of paclitaxel was decreased in the microemulsion formulation compared with Taxol (R), suggesting faster absorption. Based on these results, we conclude that oral bioavailability of paclitaxel is significantly improved by co-administration with silymarin, an inhibitor of the P-gp efflux pump and by microemulsion formulation. (C) 2011 Elsevier B.V. All rights reserved.